Fagron, the leading global player in pharmaceutical compounding, is pleased to announce two strategic acquisitions that further strengthen its global footprint and diversify its capabilities. These transactions include Amber Compounding Pharmacy, a well-established operator in the attractive compounding markets of Singapore and Malaysia, representing Fagron’s second significant step in the APAC region following its earlier acquisition of Bella Corp in Australia, as well as Vepakum, a specialised packaging manufacturer that expands Fagron’s presence into this new vertical in Brazil. The closing of the Vepakum acquisition is conditional on antitrust clearance from the Brazilian competition authorities.

Through these acquisitions, Fagron remains firmly committed to advancing its growth strategy, driving operational excellence, and maintaining prudent balance sheet management, key enablers that support sustained value creation and position Fagron for long-term success.

The combined businesses are expected to generate approximately €26 million in annual revenue, with an EBITDA margin exceeding Fagron’s current group margin, while the aggregate purchase price amounts to roughly €55 million. This results in an average EV to EBITDA multiple of around 8x.

Additionally, the Company has obtained a license for its new Anazao Health facility in Tampa from the California State Board of Pharmacy, enabling the shipment of patient-specific compounded medications to California. This development reinforces Fagron’s presence in one of the largest and most tightly regulated healthcare markets in the United States, further enhancing its ability to serve patients and healthcare providers with high-quality, customised solutions.